Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
2023-10-10
临床2期并购
Preview
来源: FierceBiotech
The now-shuttered phase 2 study was evaluating the NR2B negative allosteric modulator alongside standard-of-care treatment to quickly reduce MDD symptoms.
Novartis rolled the dice in 2020 with a $210 upfront acquisition of long-time neuroscience partner Cadent Therapeutics. But the bet seems to have come up empty, as the Swiss pharma discontinues a mid-phase major depressive disorder program.
The decision to shelve MIJ821 in patients with major depressive disorder (MDD) experiencing suicidal ideation with intent followed a “benefit-risk assessment of available data,” a spokesperson said in an emailed statement. “No new or changing safety signal was identified for study participants.”
The now-shuttered phase 2 study was evaluating the NR2B negative allosteric modulator alongside standard-of-care treatment to quickly reduce MDD symptoms. According to ClinicalTrials.gov, the trial was set to wrap this past July. The spokesperson did not confirm if the study met its goal.
When Novartis acquired Cadent less than three years ago, the pharma took ownership of the company's crown jewel CAD-9303, an investigational schizophrenia med being studied in a phase 1 trial at the time, and movement disorder program CAD-1883.
That leaves one indication for MIJ821 in treatment-resistant depression, something Novartis has been testing since 2015—years before the acquisition—when it exclusively licensed the asset from Cadent. The intravenous injection is currently being tested in a phase 2 trial, according to Novartis’ pipeline, though the company declined to confirm the ongoing status of the study.
The Big Pharma will share an updated pipeline as part of its third-quarter earnings call on Oct. 24, the spokesperson said.
MIJ821 is Novartis’ only therapy in development for MDD. The rest of the company’s neuroscience portfolio focuses on migraines, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, progressive supranuclear palsy and spinal muscular atrophy.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。